BioSpace News Archive

Eliem Therapeutics reported results from its Phase 2a clinical trial investigating ETX-810 for the treatment of diabetic peripheral neuropathic pain, and provided an update on the status of the ETX-155 clinical program in epilepsy and depression.

Bausch + Lomb, and Novaliq GmbH, today announced that data from the first pivotal Phase 3 trial (GOBI) of NOV03 (perfluorohexyloctane), which is being investigated as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).

Biotheryx, Inc. today announced the appointment of Jeff Caravella as Chief Financial Officer.

Generate Biomedicines today announced that Sean Martin has been named the company’s Chief Legal Officer and General Counsel, overseeing all legal and compliance matters.

At the Experimental Nuclear Magnetic Resonance Conference (ENC 2022), Bruker demonstrates a novel and remarkably compact 1.0 GHz NMR magnet, operating at 4.2 Kelvin, for structural biology applications in single-story standard laboratories.

Antibe Therapeutics Inc. today announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference being held in person on May 2-3, 2022.

Ocugen, Inc. announced today that the independent Data and Safety Monitoring Board (DSMB) for its Phase 1/2 clinical trial of OCU400 reviewed safety data based on dosing to date and recommended that the study proceed with enrolling additional subjects.

Actinium Pharmaceuticals, Inc. today highlighted data from full patient enrollment in the pivotal Phase 3 SIERRA trial of Iomab-B.

Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report first quarter 2022 financial results before the market opens on Monday, May 9, 2022.

Gossamer Bio, Inc. today announced topline results from its Phase 2 SHIFT-UC Study clinical trial studying GB004 in patients with mild-to-moderate active ulcerative colitis (UC).